Mutated netrin-4, fragments thereof and their use as medicines

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/18 (2006.01) C07K 14/475 (2006.01)

Patent

CA 2587921

The invention concerns the use of a netrin selected among netrin-4, mutated netrin-4, netrin-1, netrin Gl or netrin-3, or one of their fragments or a nucleotide sequence encoding one of said netrins or one of said fragments, or an anti-idiotypic antibody of one of said netrins or of one of said fragments, or of a Fab fragment of said anti-idiotypic antibodies, for preparing a medicine for preventing or treating tumoral or non-tumoral pathologies.

La présente invention concerne l'utilisation d'une nétrine choisie parmi la nétrine 4, la nétrine 4 mutée, la nétrine 1, la nétrine Gl ou la nétrine 3, ou l'un de leurs fragments, ou d'une séquence nucléotidique codant pour l'une de ces nétrines ou l'un de ces fragments, ou d'un anticorps anti-idiotypique de l'une de ces nétrines ou de l'un de ces fragments, ou d'un fragment Fab desdits anticorps anti-idiotypiques, pour la préparation d'un médicament destiné à la prévention ou au traitement des pathologies tumorales ou non tumorales.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Mutated netrin-4, fragments thereof and their use as medicines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mutated netrin-4, fragments thereof and their use as medicines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutated netrin-4, fragments thereof and their use as medicines will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2029383

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.